cirpublications.com-CHmJ-1790880680-o275241982 1790880680 Clinical Intelligence Research Press info@cirpublications.com Clinical Intelligence Research Press Journal of Health Informatics and Digital Systems J. Health Inform. Digit. Syst. 3149-8973 2025 5 2 Nguyen Van Nam Tran Thi Hoa Le Minh Duc 2025 10.68159/o275241982 https://cirpublications.com/pub/journal/2/article/o275241982 Salzbrenner SG, McAdam-Marx C, Lydiatt M, Helding B, Scheier LM, Hill PW. Perceptions of prior authorization by use of electronic prior authorization software: a survey of providers in the United States. J Manag Care Spec Pharm. 2022;28(10):1121-8. Jones LK, Ladd IG, Gionfriddo MR, Gregor C, Evans MA, Graham J. Medications requiring prior authorization across health insurance plans. Am J Health Syst Pharm. 2020;77(8):644-8. Gaines ME, Auleta AD, Berwick DM. Changing the game of prior authorization: the patient perspective. JAMA. 2020;323(8):705-6. Bianchini ML, Kenney RM, Lentz R, Zervos M, Malhotra M, Davis SL. Discharge delays and costs associated with outpatient parenteral antimicrobial therapy for high-priced antibiotics. Clin Infect Dis. 2020;71(7):e88-e93. Contreary K, Asher A, Coopersmith J. Evaluation of prior authorization in Medicare nonemergent ambulance transport. JAMA Health Forum. 2022;3(7):e222093. Lin NU, Bichkoff H, Hassett MJ. Increasing burden of prior authorizations in the delivery of oncology care in the United States. J Oncol Pract. 2018;14(9):525-8. Doshi JA, Puckett JT, Parmacek MS, Rader DJ. Prior authorization requirements for proprotein convertase subtilisin/kexin type 9 inhibitors across US private and public payers. Circ Cardiovasc Qual Outcomes. 2018;11(1):e003939. McManus KA, Powers S, Killelea A, Tello-Trillo S, Rogawski McQuade E. Regional disparities in qualified health plans' prior authorization requirements for HIV pre-exposure prophylaxis in the United States. JAMA Netw Open. 2020;3(6):e207445. Keshwani S, Maguire M, Goodin A, Lo-Ciganic WH, Wilson DL, Hincapie-Castillo JM. Buprenorphine use trends following removal of prior authorization policies for the treatment of opioid use disorder in 2 state Medicaid programs. JAMA Health Forum. 2022;3(6):e221757. Sahni NR, Istvan B, Stafford C, Cutler D. Perceptions of prior authorization burden and solutions. Health Aff Sch. 2024;2(9):qxae096. Tseng P, Kaplan RS, Richman BD, Shah MA, Schulman KA. Administrative costs associated with physician billing and insurance-related activities at an academic health care system. JAMA. 2018;319(7):691-7. Bhattacharjee S, Murcko AC, Fair MK, Warholak TL. Medication prior authorization from the providers perspective: a prospective observational study. Res Social Adm Pharm. 2019;15(9):1138-44. Chen WC, Carpenter C, Sidiqi B, Pattison AJ, Hwang J, Pappas D, et al. Integrating prior authorization into clinical workflows for care access and practitioner experience. JAMA Netw Open. 2025;8(12):e2549093. Resneck JS Jr. Refocusing medication prior authorization on its intended purpose. JAMA. 2020;323(8):703-4. De Barros A, Abel F, Kolisnyk S, Geraci GC, Hill F, Engrav M, et al. Determining prior authorization approval for lumbar stenosis surgery with machine learning. Global Spine J. 2024;14(6):1753-9. Doshi JA, Li P, Puckett JT, Pettit AR, Raman S, Parmacek MS, et al. Trends and factors associated with insurer approval of proprotein convertase subtilisin/kexin type 9 inhibitor prescriptions. Value Health. 2020;23(2):209-16. McManus KA, Fuller B, Killelea A, Strumpf A, Powers SD, Rogawski McQuade ET. Geographic variation in qualified health plan coverage and prior authorization requirements for HIV preexposure prophylaxis. JAMA Netw Open. 2023;6(11):e2342781. Johnson M, Albizri A, Harfouche A. Responsible artificial intelligence in healthcare: predicting and preventing insurance claim denials for economic and social wellbeing. Inf Syst Front. 2023;25(6):2179-95. Pal S, Gaur M, Chaudhuri R, Kalaivanan R, Chetan KV, Praneeth BH, et al. Driving impact in claims denial management using artificial intelligence. In: International Conference on Advances in Computing and Data Sciences. Cham: Springer; 2022. p. 107-20. Su SC, Huang CC, Gung RR, Hsiung LK, Gao ZW, Tsai CE. A decision support system with artificial intelligence and natural language processing to mitigate the deduction rate of health insurance claims. Appl Sci. 2021;11(24):11623. Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, Nair B, et al. From local explanations to global understanding with explainable AI for trees. Nat Mach Intell. 2020;2(1):56-67. Rudin C. Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nat Mach Intell. 2019;1(5):206-15. Wang F, Kaushal R, Khullar D. Should health care demand interpretable artificial intelligence or accept "black box" medicine? Ann Intern Med. 2020;172(1):59-60. Bingham B, Chennupati S, Osmundson EC. Estimating the practice-level and national cost burden of treatment-related prior authorization for academic radiation oncology practices. JCO Oncol Pract. 2022;18(6):e974-e987. Nguemeni Tiako MJ, Dolan A, Abrams M, Oyekanmi K, Meisel Z, Aronowitz SV. Thematic analysis of state Medicaid buprenorphine prior authorization requirements. JAMA Netw Open. 2023;6(6):e2318487. Lenert LA, Lane S, Wehbe R. Could an artificial intelligence approach to prior authorization be more human? J Am Med Inform Assoc. 2023;30(5):989-94. Choudhury A, Perumalla S. Using machine learning to minimize delays caused by prior authorization: a brief report. Cogent Eng. 2021;8(1):1944961. Mello MM, Rose S. Denial-artificial intelligence tools and health insurance coverage decisions. JAMA Health Forum. 2024;5(3):e240622. Miller AP, Shor R, Waites T, Wilson BH. Prior authorization reform for better patient care. J Am Coll Cardiol. 2018;71(17):1937-9.